PTPRT Could Be a Treatment Predictive and Prognostic Biomarker for Breast Cancer

Lun Li, Feng Xu, Pingfang Xie, Liqin Yuan, and Meirong Zhou

Department of General Surgery, Xiangya Second Hospital, Central South University, No. 139 Middle People Road, Changsha, Hunan 410011, China

Correspondence should be addressed to Meirong Zhou; zmr247@csu.edu.cn

Received 29 June 2021; Accepted 26 July 2021; Published 10 August 2021

Academic Editor: Nagarajan Raju

Copyright © 2021 Lun Li et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The role of PTPRT in breast cancer was not comprehensively explored and well analyzed. Our study comprehensively searched available databases to analyze the clinical role of PTPRT in breast cancer. We found PTPRT was an antioncogene and could be used to distinguish different stages, age groups, molecular types, and grades for breast cancer. PTPRT might be primary resistance biomarkers for taxane, anthracycline, and ixabepilone but not be acquired resistance biomarkers. Higher PTPRT expression levels were associated with longer overall survival and recurrence-free survival. PTPRT was negatively associated with Ki67 and CDK4/6 but positively associated with BCL-2. PTPRT might be associated with cell cycle and microtubule, and tumor infiltration in B cell and macrophage cell. PTPRT could predict chemotherapy effectiveness and prognosis for breast cancer patients. PTPRT might inhibit tumor growth via disrupting the microtubule dynamics and cell cycle in breast cancer.

1. Introduction

PTPRT belongs to the type IIB RPTP subfamily, which consisted of an extracellular domain (a meprin/A5/PTP μ domain, an Ig domain, and four fibronectin type III repeats), a transmembrane domain, a juxtamembrane region, and two phosphatase domains (D1 and D2) [1]. PTPRT plays in suppressing tumor growth and cell adhesion in various cancers, including colorectal cancer [2], hepatocellular carcinoma [3], prostate cancer [4], lung squamous cell carcinoma [5], esophageal squamous cell carcinoma [6], and glioma [7]. Previous review showed PTPRT as a tumor suppressor might be involved in cell cycle and cell adhesion [1]. Five missense mutations in the most commonly altered PTPRT were found to reduce phosphatase activity, and expression of wild-type but not a mutant PTPRT in human cancer cells inhibited cell growth [8]. Zhang et al. showed deletion of the fibronectin type III repeats (FNIII) of PTPRT result in defective cell-cell aggregation, which suggest the inactivation of PTPRT might lead to cancer progression by disrupting cell-cell adhesion [9]. Available studies about the PTPRT were limited, and about 66 studies were found in Pubmed. Few studies were conducted about the PTPRT signaling pathway. Zhang et al. identified signal transducer and activator of transcription 3 (STAT3) as a substrate of PTPRT. They showed PTPRT specifically dephosphorylated STAT3 at a tyrosine at amino acid Y705 and overexpression of normal PTPRT in colorectal cancer cells reduced the expression of STAT3 target genes [10]. Other studies identified miR-532-3p [3], miR-218 [6], miR-215 [11], and miR-888 [12] might regulate and mediate the expression of PTPRT. Schettini et al. used a novel methodology to detect surface antigen to develop ADC and CAR-T against breast cancer already and identified PTPRT as a novel potential target for molecular Luminal A or immunohistochemical HR+/HER2-negative BC [13]. In order to analyze the clinical role of PTPRT in breast cancer, we comprehensively searched available databases to summarize the treatment predictive and prognostic values of PTPRT.

2. Materials and Methods

No Institutional Review Board (IRB) approval was needed for this study. Available databases based on TCGA and
GEO data were searched using PTPRT and breast cancer. Three databases based on TCGA data including GEPIA (http://gepia.cancer-pku.cn/), UALCAN (http://ualcan.path.uab.edu/analysis.html), and Linkedomics (http://www.linkedomics.org/login.php) were used to analyze the differences of PTPRT expression in different age groups, stages, and molecular types, as well as the prognostic value of PTPRT in breast cancer. Three databases based on GEO data including bc-GenExMiner v4.3 (http://bcgenex.centregauducheau.fr/BC-GEM/GEM-requete.php), ROCPlot (http://www.rocplot.org/user/login), and KMPLOT (http://kmplot.com/) were used to analyze the differences of PTPRT expression in different age groups, stages, and molecular types, as well as the predictive values of different drugs and the prognostic value of PTPRT in breast cancer.

Three databases based on TCGA data about DNA methylation including UALCAN (http://ualcancer.path.uab.edu/analysis.html), Wanderer (http://maplab.imppc.org/wanderer/), and Methsurv (https://biit.cs.ut.ee/methsurv/) were used to retrieve the CpG sites of PTPRT and their methylation including UALCAN (http://ualcan.path.uab.edu/analysis.html), Wanderer (http://maplab.imppc.org/wanderer/), and Methsurv (https://biit.cs.ut.ee/methsurv/) were also searched to obtain the PTPRT expression based on linkedomics database (http://www.linkedomics.org/login.php) were used to analyze the differences of PTPRT expression in diverse acquired resistance cell lines and the relationships between PTPRT and ER, PGR, ERBB2, Ki67. Other genes that might be associated with PTPRT were explored using Cytoscape based on available public databases.

The most correlated coexpressed genes were retrieved based on linkedomics database (r > 0.4 or r < −0.4, p < 0.05). These genes were then submitted to Gprofiler (https://biit.cs.ut.ee/gprofiler/gost) for GO enrichment analysis and Kobas (http://kobas.cbi.pku.edu.cn/anno_iden.php) for KEGG analysis. TIMER (https://cistrome.shinyapps.io/timer/) is a comprehensive resource for the systematical analysis of immune infiltrates across diverse cancer types.

3. Results

3.1. The Expression of PTPRT in Breast Cancer. Using TCGA data, the expression level of PTPRT in breast cancer tissue is lower than that in adjacent normal breast tissue (median 2.24 vs. 4.41 TPM (transcript per million), p < 0.001). The expression level of PTPRT in stage 1 to 4 breast cancer tissues was lower than that in adjacent normal breast tissue (stage 1 vs. stage 2 vs. stage 3 vs. stage 4: 3.68 vs. 2.01 vs. 1.92 vs. 0.83). The expression level of PTPRT decreased from stage 1 to stage 4, and there were statistical significances between stage 1 and 4, stage 2 and 4 (p < 0.05). Interestingly, the expression level of PTPRT increased with age from 1.80 TPM in patients aged 20 to 40 years to 2.41 TPM in patients aged 61 to 80 years. Luminal A/B breast cancer patients have higher PTPRT expression level than that in adjacent normal breast cancer tissues (5.21 vs. 4.41, p < 0.001), while HER2+ (median 0.16 vs. 4.41, p < 0.001) and TNBC (median 0.09 vs. 4.41, p < 0.001) patients have lower PTPRT expression than that in adjacent normal breast cancer tissues (Figure 1).

Based on TCGA data, PTPRT was higher in pT1 breast cancer patients (RNA-Seq by Expectation-Maximization (RSEM), log2, median 9.46, IQR 6.42-11.02) than those in pT2 (median 8.41, IQR 5.40-10.60) and pT4 (median 7.45, IQR 5.18-9.85), and similar to that in pT3 breast cancer patients (median 8.92, IQR 5.58-10.46). However, there were statistical significances in the PTPRT expression levels between pathologic N0 (median 2.30, IQR 0.27 9.03), N1 (median 2.43, IQR 0.36 11.31), N2 (median 1.80, IQR 0.34 8.98), and normal (median 4.41, IQR 2.38 7.70); no significance was found between N3 (median 2.42, IQR 0.23 7.76) and normal (Figure 1). Based on GEO data, the expression level of PTPRT decreased with the increase of Scar-Bloom-Richardson (SBR) grade (SBR1 > SBR2 > SBR3, p < 0.001, 6810 patients). Those patients with lymph node metastases were of lower PTPRT levels (p < 0.0001, 7474 patients). The PTPRT expression levels in patients with different ages were similar to that in TCGA databases. The older the patients, the higher the PTPRT expressions (7434 patients, 70 − 97 > 40 − 70 > 21 − 40, p < 0.05). Luminal A breast cancer patients were of the highest level of PTPRT, which was higher than that in normal-like breast cancer (p < 0.05). HER2+ and basal-like breast cancer were of lower PTPRT level than that in normal-like breast cancer, and basal-like breast cancer was of the lowest PTPRT expression level. There was no statistical significance between luminal B and normal-like breast cancer (Figure 2).

3.2. The Promoter Methylation Level of PTPRT in Breast Cancer. Based on TCGA data, the promoter methylation level of PTPRT was higher in breast cancer tissues than those in adjacent normal breast tissue (0.067 vs. 0.039, p = 1.62E − 12). The promoter methylation level of PTPRT increased from stage 1 to stage 4 (0.06 vs. 0.07 vs. 0.08 vs. 0.09); however, there was a statistical difference between stage 1 and 2 (p = 0.01). Also, this increased with the age (21-40 vs. 41-60 vs. 61-80: 0.06 vs. 0.06 vs. 0.07); however, statistical differences were only found between patients age 21 and 40 years old with 41-60, 61-80, or 81-100 years old. Only CpG site cg23357198 could predict survival (high vs. low: HR = 2.38, p = 0.04) (Figure 3).

3.3. The Predictive Values of PTPRT in Breast Cancer Treatment. Based on rocplot.plot, among those patients who received neoadjuvant taxane (AUC = 0.59, p = 3.1e − 7), anthracycline (AUC = 0.60, p = 1.1e − 11), ixabepilone (AUC = 0.61, p = 0.04), and FAC (AUC = 0.6, p = 6.6e − 3), the PTPRT expression level was higher in no-responders than those in responders. PTPRT might not predict the effectiveness of aromatase inhibitor (AUC = 0.54, p = 0.33), trastuzumab (AUC = 0.56, p = 0.09), lapatinib (AUC = 0.59, p = 0.13), FEC (AUC = 0.51, p = 0.44), and CMF (AUC = 0.52, p = 0.37).

Among those patients who received adjuvant CMF (AUC = 0.6, p = 0.09), FAC (AUC = 0.53, p = 0.4), aromatase inhibitor (AUC = 0.61, p = 0.21), trastuzumab (AUC = 0.50, p = 0.48), taxane (AUC = 0.51, p = 0.14), and FEC (AUC = 0.56, p = 0.33), PTPRT might not predict the recurrence-free survival of the breast cancer patients. A high level of PTPRT might be associated with more survivors among those who received adjuvant tamoxifen (AUC = 0.59, p = 7.1e − 4), but fewer survivors in those who received anthracycline (AUC = 0.56, p = 2.9e − 2) (Figure 4).
Figure 1: Continued.
Figure 1: The expression of PTPRT in breast cancer in TCGA. (a) The expression of PTPRT between tumor and normal breast cancer tissue. (b) The expression of PTPRT in breast cancer across different molecular types. (c) The expression of PTPRT in breast cancer across different age groups. (d) The expression of PTPRT in breast cancer across different stages. (e) The expression of PTPRT in breast cancer across different tumor sizes. (f) The expression of PTPRT in breast cancer across different node statuses.
Box plot of $PTPRT$ expression according to PAM50 subtypes

(a) Box plot of $PTPRT$ expression according to age

(b) Figure 2: Continued.
3.4. The Prognostic Values of PTPRT in Breast Cancer. KM plot showed that high PTPRT expression levels were associated with longer survivals in terms of overall survival (HR 0.6, 95% CI 0.48–0.75, p = 5.1E−6) and recurrence-free survival (HR 0.6, 95% CI 0.54–0.68, p < 1E−16). This was consistent with the prognostic analysis results from TCGA and Breast Cancer Gene-Expression Miner v4.3 data-sets, which also confirmed the survival benefits of high PTPRT. The
Promoter methylation level of PTPRT in BRCA

(a)

TCGA samples

Normal
(n = 97)

Primary tumor
(n = 793)

Promoter methylation level of PTPRT in BRCA

(b)

TCGA samples

Normal
(n = 97)

Stage 1
(n = 127)

Stage 2
(n = 442)

Stage 3
(n = 200)

Stage 4
(n = 11)

Figure 3: Continued.
The prognostic values of PTPRT were consistent across different molecular types of breast cancer.

3.5. The Expression of PTPRT between Acquired Drug-Resistant and Parental Cell Lines. PTPRT might not be acquired resistance biomarkers for tamoxifen (MCF, GSE26459, logFC = 0.57, p = 0.09; GSE67916, logFC = −0.20, p = 0.13), epirubicin (MCF7, GSE54326, logFC = −0.64, p = 0.25; SKBR3, GSE54326, logFC = 1.27, p = 0.36; MDA-MB-231, GSE54326, logFC = 0.31, p = 0.65), trastuzumab (BT474, GSE15043, logFC = −0.01, p = 0.92; BT474, GSE119397, logFC = 0.007, p = 0.95), T-DM1 (BT474, GSE100192, logFC = −0.002, p = 0.98), lapatinib (BT474, GSE16179, logFC = −0.496, p = 0.70; SKBR3, GSE38376, logFC = 0.18, p = 0.14; SKBR3, GSE52707, logFC = 0.26, p = 0.03; BT474, GSE84896, logFC = 0.29, p = 0.001), paclitaxel (MDA-MB-231, GSE90564, logFC = −0.42, p = 0.07; MDA-MB-231, GSE12791, logFC = 0.87, p = 0.29) and BMS-554417 (MCF, GSE18912, logFC = −0.024, p = 0.79). However, PTPRT might be an acquired resistance biomarker for doxorubicin among MCF7 cell lines (MCF7, GSE76540, logFC = −0.12, p = 0.03).

3.6. The Relationship between PTPRT and ER, PR, HER2, Ki67. According to bc-GenExMiner v4.3, estrogen receptor or progesterone receptor-positive (IHC) breast cancer
Figure 4: Continued.
Figure 4: Continued.
patients were with higher PTPRT levels, while HER2+ (IHC) breast cancer patients were with lower PTPRT level. According to TCGA data, PTPRT was positively associated with ESR1 ($R = 0.5$, $p = 3.1e-128$); however, PTPRT was negatively associated with ERBB2 ($R = -0.09$, $p = 0.004$), KI67 ($R = -0.26$, $p = 1e-18$). Meanwhile, PTPRT was positively associated with BCL-2 ($R = 0.54$, $p = 1.6E - 83$). Based on GEO datasets, estrogen receptor alpha knockdown (GSE37473, logFC = 0.06, $p = 0.61$) and HER2 siRNA (GSE71347, logFC = 0.22, $p = 0.09$) did not influence the expression of PTPRT (Figure 5).

### 3.7. PTPRT Might Inhibit Tumor Growth via Disrupting the Microtubule Dynamics and Cell Cycle

According to the KEGG and GO enrichment analysis of the genes that were associated with PTPRT ($r > 0.4$ or $r < -0.4$, $p < 0.05$), we found PTPRT might be associated with cell cycle and microtubule-based process. For biological process, PTPRT might be associated with the mitotic cell cycle, microtubule-based process, mitotic cell cycle process, cell cycle, cell division, microtubule cytoskeleton organization, and cell cycle process. For cellular component, PTPRT was associated with the microtubule cytoskeleton, while for molecular function, PTPRT was associated with microtubule motor activity, protein binding, and motor activity (Figure 6).

Among the genes in microtubule motor activity (biological process, GO:0007017, microtubule-based process; molecular function, GO:0003777, microtubule motor activity; cellular component, GO:0015630, microtubule cytoskeleton), 14 genes (BBS4, DNAH5, DNAH7, DYNC2H1,
Box plot of PTPRT expression according to ER (IHC)

(a)

Box plot of PTPRT expression according to PR (IHC)

(b)

Box plot of PTPRT expression according to HER2 (IHC)

(c)

Log2 (ESR1 TPM) vs Log2 (PTPRT TPM)

(d)

Figure 5: Continued.
Figure 5: Continued.
3.8. PTPRT in Tumor-Infiltrating Immune Cells. PTPRT was positively associated with CD8+ T cell (r = 0.18), CD4+ T cell (r = 0.25), Neutrophil cell (r = 0.44), stem cell (r = 0.47), and M2 macrophage cell (r = 0.30) infiltration but negatively associated with B cell (r = −0.31), DC cell (r = −0.33), NK cell (r = −0.18), monocyte cell (r = −0.22), M0 macrophage cell (r = −0.21), and M1 macrophage cell (r = −0.35) (Figure 8). High PTPRT independently predicts better outcome (HR = 0.91, 95% CI 0.86–0.97, p = 0.002) in breast cancer corrected for patient age, stage, and TIICs (Table 1).

4. Discussion

PTPRT is an antioncogene and plays important roles in various cancers, including colorectal cancer [2], hepatocellular carcinoma [3], prostate cancer [4], lung squamous cell carcinoma [5], and glioma [7]. Several studies showed overexpressed PTPRT might inhibit tumor cell growth acting as a putative tumor suppressor in cancer cell culture [2–5, 7, 8]. Animal studies showed PTPRT knockout increases the size of mouse colon tumors in the Apcmin+/- genetic background, suggesting that inactivation of PTPRT promotes tumor progression [14]. Our study analyzed the role of PTPRT in breast cancer, and we found the PTPRT mRNA level could be biomarkers for different stages, age groups, molecular types, and grades for breast cancer, as well as prognostic biomarkers for breast cancer. Based on our analysis, it is obvious that a larger tumor was associated with a lower PTPRT expression level. Meanwhile, breast tumor with high PTPRT was associated with low proliferation rate (measured by Ki67) and high apoptotic rates (measured by BCL-2). All these data suggest PTPRT might inhibit tumor growth in breast cancer as a tumor suppressor. The signal transducer and activator of transcription 3 (STAT3) protein is a major player in various biological processes, including cell growth, differentiation, and regulation of gene expression. It has been shown that STAT3 is involved in the development of various cancers, including breast cancer. Therefore, targeting STAT3 by PTPRT could be a potential therapeutic strategy for breast cancer treatment.
Figure 6: Continued.
Figure 6: The enrichment analysis for PTPRT in breast cancer. (a) The biological process. (b) The molecular function. (c) The cellular component. (d) The KEGG pathway.
Figure 7: Continued.
Figure 7: Continued.
transcription factor involved in many cellular processes, such as cell growth and proliferation, differentiation, migration, and cell death or cell apoptosis [15]. Plenty of evidence suggested PTPRT might negatively regulate STAT3 activation by dephosphorylation of the tyrosine residue [15–18]. STAT3 may be activated by loss-of-function of negative regulators of STAT3, including by promoter hypermethylation of PTPRT [17]. This was confirmed in breast cancer, and PTPRT was negatively associated with STAT3, while the promoter methylation level of PTPRT was positively associated with STAT3 based on TCGA data.

PTPRT might predict the effectiveness of primary resistance biomarkers for taxane, anthracycline, and ixabepilone, which all displayed better effectiveness in breast cancer disease control [19–21], but not be acquired resistance biomarkers. Taxane were potent cytotoxic microtubule-stabilizing agents, and they exert their action through induction of apoptosis through phosphorylation of bcl-2 and inhibition of cell proliferation [22], as well as selectively disrupting the microtubule dynamics, inducing mitotic arrest that leads to cell death [23]. Anthracyclines, which belong to cell cycle nonspecific agents, are a class of potent and widely used cytotoxic drugs, derived from antibiotics that inhibit DNA and RNA synthesis by intercalating between base pairs of the DNA/RNA strand [24]. Ixabepilone bind to the β-tubulin subunit of the α, β dimer of microtubules, inducing microtubule polymerization, stabilization, and formation of abnormal mitotic spindles, which in turn cause G2/M arrest and apoptosis [25, 26]. The cell signaling pathways regulated by PTPRT largely remain to be elucidated. Based on our GO and KEGG analysis, we could find PTPRT might be associated with the cell cycle and microtubule-based process. It was reported that microtubules are cytoskeletal structures that play a pivotal role in cell division, locomotion, and intracellular transport [27]. During mitosis, microtubules, which consist of α- and β-tubulin, represent a major structural component of the spindle apparatus, which is required for the separation of sister chromatids [28]. Our analysis indicated that PTPRT was significantly associated with several genes that were involved in microtubule motor activity. This might explain why PTPRT could be a primary resistance biomarker for taxane, anthracycline, and ixabepilone.

Acquired drug resistance to chemotherapy and targeted therapy treatment is unavoidable, creating a clinically challenging problem, which represents a major challenge in for various types of cancers [29, 30]. Acquired resistance develops after a significant initial response over the course of several months [31]. Hammerlindl et al. [31] proposed that treatment will initially facilitate cellular reprogramming towards the slow-cycling drug-tolerant phenotype and continuous drug exposure will eventually lead to reactivation of transcriptional activity and regain of proliferative capacity. These will further stabilize their drug-tolerant transcriptional profile to become permanent drug resistant. According to their theory, PTPRT stays stable during the acquired resistance process, which means the expression of PTPRT did not change during the long drug exposure. So PTPRT might be a good primary resistance biomarker for taxane, anthracycline, and ixabepilone.

Based on our data, although PTPRT was coexpressed with ESR1 and ERBB2, the status of ESR1 and ERBB2 did not affect the expression of PTPRT. Whether PTPRT affects the expression of ESR1 and ERBB2 was unclear. Based on our study, higher PTPRT was associated with longer survival in different molecular types based on KMplot data, and this
Figure 8: Continued.
Figure 8: The relationship between PTPRT and tumor infiltration. (a) The relationship between PTPRT and CD4+ T cell infiltration. (b) The relationship between PTPRT and CD8+ T cell infiltration. (c) The relationship between PTPRT and Treg cell infiltration. (d) The relationship between PTPRT and B cell infiltration. (e) The relationship between PTPRT and Monocyte cell infiltration. (f) The relationship between PTPRT and macrophage M0 cell infiltration. (g) The relationship between PTPRT and macrophage M1 cell infiltration. (h) The relationship between PTPRT and macrophage M2 cell infiltration. (i) The relationship between PTPRT and Neutrophil cell infiltration. (j) The relationship between PTPRT and dendritic cell infiltration. (k) The relationship between PTPRT and NK cell infiltration. (l) The relationship between PTPRT and Hematopoietic cell infiltration.
GEO data were included to explore the role of PTPRT in breast cancer. In our study, not only TCGA but also PTPRT expression was not a significant predictor of taxane, anthracycline, and ixabepilone efficacy. We confirmed that PTPRT might inhibit tumor growth via disrupting the microtubule dynamics and cell cycle in breast cancer. Our study comprehensively analyzed the role of PTPRT in breast cancer. In our study, not only TCGA but also GEO data were included to explore the role of PTPRT in breast cancer. We found PTPRT might predict the effectiveness of taxane, antracycline, ixabepilone, and the prognostic values. We confirmed that PTPRT might inhibit tumor growth in breast cancer, which might be due to microtubule dynamics. However, our study still has its own limitations: first, all of our analyses were based on RNA sequence data. Our study was based on RNA sequence, whether q-pcr or IHC results still have the predictive values for the effectiveness of taxane, antracycline, and ixabepilone and prognosis or not. Second, population heterogeneity might exist in this study across different datasets, although we used GEO datasets to validate the results in TCGA data. Third, PTPRT might be an inhibitor of tumor growth via disrupting the microtubule dynamics and cell cycle in breast cancer. This lacked in vivo and in vitro experiments to validate our study results. Future studies are needed about how PTPRT affects the drug effectiveness and breast cancer prognosis, as well as microtubule dynamics and cell cycle.

5. Conclusion

PTPRT expression was not affected by ER or HER2 expression, but PTPRT could distinguish Luminal A and TNBC, HER2+ breast cancer. PTPRT could be used as biomarkers to predict taxane, anthracycline, and ixabepilone effectiveness and prognosis for breast cancer patients. PTPRT might be an inhibitor of tumor growth via disrupting the microtubule dynamics and cell cycle in breast cancer.

Table 1: Multivariable Cox proportional hazard model for PTPRT in breast cancer.

|                  | Coef | HR  | 95%CI_lower | 95%CI_upper | p value |
|------------------|------|-----|-------------|-------------|---------|
| Age              | 0.034| 1.034 | 1.019        | 1.05        | <0.0001 |
| Gender: male     | 0.154| 1.167 | 0.159        | 8.561       | 0.879   |
| Race: Black      | -0.4 | 0.67  | 0.196        | 2.297       | 0.524   |
| Race: White      | -0.58| 0.56  | 0.173        | 1.812       | 0.333   |
| Stage 2          | 0.479| 1.615 | 0.848        | 3.075       | 0.145   |
| Stage 3          | 1.307| 3.693 | 1.903        | 7.167       | <0.0001 |
| Stage 4          | 2.58 | 13.201| 5.845        | 29.817      | <0.0001 |
| Purity           | 0.264| 1.302 | 0.448        | 3.788       | 0.628   |
| B_cell           | -1.393| 0.248 | 0.002        | 28.446      | 0.565   |
| CD8_Tcell        | -1.735| 0.176 | 0.012        | 2.571       | 0.204   |
| CD4_Tcell        | 1.062| 2.891 | 0.053        | 156.739     | 0.602   |
| Macrophage       | 3.336| 28.094| 1.591        | 496.112     | 0.023   |
| Neutrophil       | 1.629| 5.1   | 0.018        | 1441.713    | 0.572   |
| Dendritic        | -0.735| 0.48  | 0.055        | 4.2         | 0.507   |
| PTPRT            | -0.092| 0.912 | 0.86         | 0.968       | 0.002   |

was confirmed after adjusting several clinical factors based on TCGA data.

Data Availability

The data used to support the findings of this study are included within the article.

Conflicts of Interest

The authors declare that there is no conflict of interest regarding the publication of this paper.

References

[1] A. Scott and Z. Wang, “Tumour suppressor function of tyrosine phosphatase receptor-T,” Bioscience Reports, vol. 31, no. 5, pp. 303–307, 2011.

[2] K. Goryca, M. Kulecka, A. Paziewska et al., “Exome scale map of genetic alterations promoting metastasis in colorectal cancer,” BMC Genomics, vol. 19, no. 1, p. 85, 2018.

[3] Y. Wang, Z. Yang, L. Wang et al., “miR-532-3p promotes hepatocellular carcinoma progression by targeting PTPRT,” Biomedicine & Pharmacotherapy, vol. 109, pp. 991–999, 2019.

[4] A. S. Nikitina, E. I. Sharova, S. A. Danilenko et al., “Novel RNA biomarkers of prostate cancer revealed by RNA-seq analysis of formalin-fixed samples obtained from Russian patients,” Oncotarget, vol. 8, no. 20, pp. 32990–33001, 2017.

[5] M. Choi, H. Kadara, J. Zhang et al., “Mutation profiles in early-stage lung squamous cell carcinoma with clinical follow-up and correlation with markers of immune function,” Annals of Oncology, vol. 28, no. 1, pp. 83–89, 2017.

[6] Y. Yao, J. Shao, J. Wu et al., “The functional variant in the 3'UTR of PTPRT with the risk of esophageal squamous cell carcinoma in a Chinese population,” Cellular Physiology and Biochemistry, vol. 36, no. 1, pp. 306–314, 2015.

[7] A. M. Bourgonje, K. Verrijp, J. T. G. Schepens et al., “Comprehensive protein tyrosine phosphatase mRNA profiling identifies new regulators in the progression of glioma,” Acta Neuropathologica Communications, vol. 4, no. 1, pp. 1–14, 2016.

[8] Z. Wang, D. Shen, D. W. Parsons et al., “Mutational analysis of the tyrosine phosphatome in colon cancers,” Science, vol. 304, no. 5674, pp. 1164–1166, 2004.

[9] P. Zhang, S. Becka, S. E. Craig, D. T. Lodowski, S. M. Brady-Kalnay, and Z. Wang, “Cancer-derived mutations in the fibronectin III repeats of PTPRT/PTPrho inhibit cell-cell aggregation,” Cell Communication & Adhesion, vol. 16, no. 5–6, pp. 146–153, 2009.

[10] X. Zhang, A. Guo, J. Yu et al., “Identification of STAT3 as a substrate of receptor protein tyrosine phosphatase T,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 10, pp. 4060–4064, 2007.

[11] F. Liu, X. You, X. Chi et al., “Hepatitis B virus X protein mutant HBxΔ127 promotes proliferation of hepatoma cells through up-regulating miR-215 targeting PTPRT,” Biochemical and Biophysical Research Communications, vol. 444, no. 2, pp. 128–134, 2014.

[12] S. Huang, M. Cai, Y. Zhou, Q. Wang, and L. Chen, “miR-888 in MCF-7 side population sphere cells directly targets E-cadherin,” Journal of Genetics and Genomics, vol. 41, no. 1, pp. 35–42, 2014.

[13] F. Schettini, P. Barbao, F. Braso-Maristany et al., “Identification of cell surface targets for CAR-T cell therapies and
antibody-drug conjugates in breast cancer,” *ESMO Open*, vol. 6, no. 3, article 100102, 2021.

[14] Y. Zhao, A. Scott, P. Zhang et al., “Regulation of paxillin-p130-PISK-AKT signaling axis by Src and PTPRT impacts colon tumorigenesis,” *Oncotarget*, vol. 8, no. 30, pp. 48782–48793, 2017.

[15] M. Kim, L. D. Morales, I. S. Jang, Y. Y. Cho, and D. J. Kim, “Protein tyrosine phosphatases as potential regulators of STAT3 signaling,” *International Journal of Molecular Sciences*, vol. 19, no. 9, p. 2708, 2018.

[16] T. A. Chan and A. Heguy, “The protein tyrosine phosphatase receptor D, a broadly inactivated tumor suppressor regulating STAT function,” *Cell Cycle*, vol. 8, no. 19, pp. 3063-3064, 2009.

[17] N. D. Peyser, M. Freilino, L. Wang et al., “Frequent promoter hypermethylation of PTPRT increases STAT3 activation and sensitivity to STAT3 inhibition in head and neck cancer,” *Oncogene*, vol. 35, no. 9, pp. 1163–1169, 2016.

[18] N. D. Peyser, L. Wang, Y. Zeng et al., “STAT3 as a chemoprevention target in carcinogen-induced head and neck squamous cell carcinoma,” *Cancer Prevention Research (Philadelphia, Pa.)*, vol. 9, no. 8, pp. 657–663, 2016.

[19] R. Caparica, M. Bruzzone, F. Poggio, M. Ceppi, E. de Azambuja, and M. Lambertini, “Anthracline and taxane-based chemotherapy versus docetaxel and cyclophosphamide in the adjuvant treatment of HER2-negative breast cancer patients: a systematic review and meta-analysis of randomized controlled trials,” *Breast Cancer Research and Treatment*, vol. 174, no. 1, pp. 27–37, 2019.

[20] J. Li, J. Ren, and W. Sun, “Systematic review of ixabepilone for treating metastatic breast cancer,” *Breast Cancer*, vol. 24, no. 2, pp. 171–179, 2017.

[21] L. Li, J. Li, K. Yang et al., “Ixabepilone plus capecitabine with capecitabine alone for metastatic breast cancer,” *Future Oncology*, vol. 6, no. 2, pp. 201–201, 2010.

[22] S. Murray, E. Briasoulis, H. Linardou, D. Bafaloukos, and C. Papadimitriou, “Taxane resistance in breast cancer: mechanisms, predictive biomarkers and circumvention strategies,” *Cancer Treatment Reviews*, vol. 38, no. 7, pp. 890–903, 2012.

[23] E. Bernabeu, M. Cagel, E. Lagomarsino, M. Moretton, and D. A. Chiappetta, “Paclitaxel: what has been done and the challenges remain ahead,” *International Journal of Pharmaceutics*, vol. 526, no. 1-2, pp. 474–495, 2017.

[24] C. Marosi, “Complications of chemotherapy in neuro-oncology,” *Handbook of Clinical Neurology*, vol. 105, pp. 873–885, 2012.

[25] D. M. Bollag, M. Q. PA, J. Zhu et al., “Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action,” *Cancer Research*, vol. 55, no. 11, pp. 2325–2333, 1995.

[26] A. De Luca, A. D’Alessio, M. R. Maiello et al., “Evaluation of the pharmacokinetics of ixabepilone for the treatment of breast cancer,” *Expert Opinion on Drug Metabolism & Toxicology*, vol. 11, no. 7, pp. 1177–1185, 2015.

[27] M. Kavallaris, “Microtubules and resistance to tubulin-binding agents,” *Nature Reviews. Cancer*, vol. 10, no. 3, pp. 194–204, 2010.

[28] T. Zhang, U. Braun, and M. Leitges, “PKD3 deficiency causes alterations in microtubule dynamics during the cell cycle,” *Cell Cycle*, vol. 15, no. 14, pp. 1844–1854, 2016.

[29] J. Foo and F. Michor, “Evolution of acquired resistance to anticancer therapy,” *Journal of Theoretical Biology*, vol. 355, no. 34, pp. 10–20, 2014.

[30] T. Yoshioka, K. Shien, T. Takeda et al., “Acquired resistance mechanisms to afatinib in HER2-amplified gastric cancer cells,” *Cancer Science*, vol. 110, no. 8, pp. 2549–2557, 2019.

[31] H. Hamerlindl and H. Schaider, “Tumor cell-intrinsic phenotypic plasticity facilitates adaptive cellular reprogramming driving acquired drug resistance,” *Cell Communication and Signaling*, vol. 12, no. 1, pp. 133–141, 2018.